Masimo announced the Masimo W1 medical watch has received FDA 510(k) clearance for over-the-counter and prescription use. Masimo W1 is the first FDA-cleared watch to provide continuous real-time oxygen saturation and pulse rate for OTC and Rx use. The FDA clearance expands the indications for the Masimo W1 in the U.S. as a medical device for use by adults in hospitals, clinics, long-term care facilities, and in the home. Developed to be comfortable and lifestyle-friendly, the Masimo W1 medical watch empowers users with untethered continuous pulse oximetry as they move about their lives – no matter where they are.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MASI:
- Masimo price target lowered to $70 from $110 at Piper Sandler
- Masimo price target lowered to $86 from $136 at Needham
- GE HealthCare, Masimo team to bring SE Pulse Oximetry to mobile platform
- Masimo price target lowered to $105 from $150 at BTIG
- Masimo price target lowered to $81 from $110 at Wells Fargo